Mereo BioPharma Group plc
MREOHealthcare|Biotechnology|GB
$0.28
+0.00 (+0.93%)
DCF Value
$0.26
Tangible Book / Share
$0.18
Cash / Share
$0.19
Ownership Breakdown
100.0%
Float
159.7M
Shares Outstanding
159.6M
Float Shares
Major Holders (30)
Combined: 78.0%
Holders of 5%+ from their latest Schedule 13D/13G filing in the last two years. Percentages are as of each filing date.
| Holder | Type | % of Class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Janus Henderson Biotech Innovation Master Fund Ltd | Investment company | 8.70% | 13,759,885 | Nov 14, 2025 | 13D/G |
| Ari Zweiman | Individual | 8.18% | 65,083,815 | Jan 6, 2026 | 13D/G |
| 683 Capital Partners, LP | Partnership | 8.18% | 65,083,815 | Jan 6, 2026 | 13D/G |
| 683 Capital Management, LLC | Investment adviser | 8.18% | 65,083,815 | Jan 6, 2026 | 13D/G |
| Mangrove Partners IM, LLC | IA, OO | 4.90% | 38,952,900 | Nov 14, 2025 | 13D/G |
| Nathaniel August | HC, IN | 4.90% | 38,952,900 | Nov 14, 2025 | 13D/G |
| Rock Springs Capital Management LP | Investment adviser | 4.20% | 33,421,235 | May 15, 2025 | 13D/G |
| Mark Bussard | HC, IN | 4.20% | 33,421,235 | May 15, 2025 | 13D/G |
| Kris Jenner | HC, IN | 4.20% | 33,421,235 | May 15, 2025 | 13D/G |
| Rock Springs Capital LLC | HC, OO | 4.20% | 33,421,235 | May 15, 2025 | 13D/G |
| Bank of America Corp /De/ | Holding company | 3.40% | 26,889,300 | Oct 28, 2026 | 13D/G |
| Rock Springs Capital Master Fund LP | Partnership | 3.20% | 25,808,055 | May 15, 2025 | 13D/G |
| FHMLSP Overage, L.L.C. | Other | 1.10% | 8,941,155 | Aug 14, 2025 | 13D/G |
| FHMLSP Overage, L.P. | Partnership | 1.10% | 8,941,155 | Aug 14, 2025 | 13D/G |
| Frazier Life Sciences Public Overage Fund, L.P. | Partnership | 1.10% | 8,941,155 | Aug 14, 2025 | 13D/G |
| Adage Capital Management, L.P. | IA, PN | 1.07% | 8,503,780 | May 12, 2025 | 13D/G |
| Robert Atchinson | HC, IN | 1.07% | 8,503,780 | May 12, 2025 | 13D/G |
| Phillip Gross | HC, IN | 1.07% | 8,503,780 | May 12, 2025 | 13D/G |
| Oleg Nodelman | HC, IN | 0.60% | 5,000,000 | Aug 14, 2026 | 13D/G |
| EcoR1 Capital Fund Qualified, L.P. | Partnership | 0.60% | 4,732,750 | Aug 14, 2026 | 13D/G |
| EcoR1 Capital, LLC | IA, OO | 0.60% | 5,000,000 | Aug 14, 2026 | 13D/G |
| Guy Levy | Individual | 0.50% | 4,234,765 | Nov 14, 2024 | 13D/G |
| Soleus GP, LLC | Other | 0.50% | 4,234,765 | Nov 14, 2024 | 13D/G |
| Soleus Capital Management, L.P. | Partnership | 0.50% | 4,234,765 | Nov 14, 2024 | 13D/G |
| Soleus Capital Group, LLC | Other | 0.40% | 3,004,210 | Nov 14, 2024 | 13D/G |
| Soleus Capital, LLC | Other | 0.40% | 3,004,210 | Nov 14, 2024 | 13D/G |
| Soleus Capital Master Fund, L.P. | Non-US institution | 0.40% | 3,004,210 | Nov 14, 2024 | 13D/G |
| Soleus PE GP III, LLC | Other | 0.20% | 1,230,555 | Nov 14, 2024 | 13D/G |
| Soleus Private Equity GP III, LLC | Other | 0.20% | 1,230,555 | Nov 14, 2024 | 13D/G |
| Soleus Private Equity Fund III, L.P. | Partnership | 0.20% | 1,230,555 | Nov 14, 2024 | 13D/G |
Insider Trades (100)
Last 4 quarters: 11,249,398 acquired · 1,774,160 disposed
| Insider | Position | Date | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jacquet Pierre | director | Feb 26, 2026 | AWARD | 106,848 | — | — | Form 4 |
| Jacquet Pierre | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| Yoskowitz Marc J | director | Feb 26, 2026 | AWARD | 96,163 | — | — | Form 4 |
| Yoskowitz Marc J | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| Shames Daniel | director | Feb 26, 2026 | AWARD | 96,163 | — | — | Form 4 |
| Shames Daniel | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| Ekblom Anders | director | Feb 26, 2026 | AWARD | 133,560 | — | — | Form 4 |
| Ekblom Anders | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| Bender Jeremy | director | Feb 26, 2026 | AWARD | 117,533 | — | — | Form 4 |
| Bender Jeremy | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| Jenkins Annalisa | director | Feb 26, 2026 | AWARD | 106,848 | — | — | Form 4 |
| Jenkins Annalisa | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| WYZGA MICHAEL S | director | Feb 26, 2026 | AWARD | 66,000 | $0.39 | $25.7K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Feb 1, 2026 | AWARD | 145,000 | $0.44 | $63.8K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Feb 1, 2026 | AWARD | 139,913 | $0.44 | $61.6K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Feb 1, 2026 | AWARD | 46,637 | $1.00 | $46.6K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Feb 1, 2026 | AWARD | 195,000 | $0.44 | $85.8K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Feb 1, 2026 | AWARD | 183,750 | $0.44 | $80.8K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Feb 1, 2026 | AWARD | 61,250 | $1.00 | $61.3K | Form 4 |
| Sermon Charles | General Counsel | Feb 1, 2026 | AWARD | 315,750 | $0.44 | $138.9K | Form 4 |
| Sermon Charles | General Counsel | Feb 1, 2026 | AWARD | 295,000 | $0.44 | $129.8K | Form 4 |
| Sermon Charles | General Counsel | Feb 1, 2026 | AWARD | 105,250 | $1.00 | $105.3K | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Feb 1, 2026 | AWARD | 1,035,000 | $0.44 | $455.4K | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Feb 1, 2026 | AWARD | 480,000 | $0.44 | $211.2K | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Feb 1, 2026 | AWARD | 345,000 | $1.00 | $345.0K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Feb 1, 2026 | AWARD | 315,750 | $0.44 | $138.9K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Feb 1, 2026 | AWARD | 280,000 | $0.44 | $123.2K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Feb 1, 2026 | AWARD | 105,250 | $1.00 | $105.3K | Form 4 |
| Yoskowitz Marc J | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| Yoskowitz Marc J | director | Feb 5, 2025 | AWARD | 13,719 | — | — | Form 4 |
| PAKIANATHAN DEEPIKA | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| Bender Jeremy | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| Bender Jeremy | director | Feb 5, 2025 | AWARD | 16,768 | — | — | Form 4 |
| Ekblom Anders | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| Ekblom Anders | director | Feb 5, 2025 | AWARD | 19,054 | — | — | Form 4 |
| WYZGA MICHAEL S | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| Shames Daniel | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| WYZGA MICHAEL S | director | Feb 5, 2025 | AWARD | 30,487 | — | — | Form 4 |
| Shames Daniel | director | Feb 5, 2025 | AWARD | 13,719 | — | — | Form 4 |
| Jenkins Annalisa | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| Jenkins Annalisa | director | Feb 5, 2025 | AWARD | 15,243 | — | — | Form 4 |
| Jacquet Pierre | director | Feb 5, 2025 | AWARD | 55,000 | $3.16 | $173.8K | Form 4 |
| Jacquet Pierre | director | Feb 5, 2025 | AWARD | 15,243 | — | — | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Jan 25, 2025 | AWARD | 116,000 | $2.91 | $337.6K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Jan 25, 2025 | AWARD | 262,000 | $2.91 | $762.4K | Form 4 |
| Sermon Charles | General Counsel | Jan 25, 2025 | AWARD | 262,000 | $2.91 | $762.4K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Jan 25, 2025 | AWARD | 154,000 | $2.91 | $448.1K | Form 4 |
| Scots-Knight Denise | Chief Executive Officer | Jan 25, 2025 | AWARD | 825,000 | $2.91 | $2.4M | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Sep 12, 2024 | SELL | 28,611 | $4.47 | $128.0K | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Sep 13, 2024 | SELL | 60,046 | $4.22 | $253.5K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Sep 12, 2024 | SELL | 5,212 | $4.47 | $23.3K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Sep 13, 2024 | SELL | 10,937 | $4.22 | $46.2K | Form 4 |
| Sermon Charles | General Counsel | Sep 12, 2024 | SELL | 9,980 | $4.47 | $44.6K | Form 4 |
| Sermon Charles | General Counsel | Sep 13, 2024 | SELL | 20,946 | $4.22 | $88.4K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Sep 12, 2024 | SELL | 9,128 | $4.47 | $40.8K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Sep 13, 2024 | SELL | 19,158 | $4.22 | $80.9K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 12, 2024 | SELL | 7,769 | $4.47 | $34.7K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 12, 2024 | SELL | 40,029 | $4.47 | $179.0K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 13, 2024 | SELL | 16,304 | $4.22 | $68.8K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 13, 2024 | SELL | 84,008 | $4.22 | $354.6K | Form 4 |
| Sermon Charles | General Counsel | Sep 11, 2024 | OPTION EX. | 65,600 | — | — | Form 4 |
| Sermon Charles | General Counsel | Sep 11, 2024 | OPTION EX. | 65,600 | — | — | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Sep 11, 2024 | OPTION EX. | 60,000 | — | — | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Sep 11, 2024 | OPTION EX. | 60,000 | — | — | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Sep 11, 2024 | OPTION EX. | 46,000 | — | — | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Sep 11, 2024 | OPTION EX. | 46,000 | — | — | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Sep 11, 2024 | OPTION EX. | 188,060 | — | — | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Sep 11, 2024 | OPTION EX. | 188,060 | — | — | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 11, 2024 | OPTION EX. | 75,000 | $1.01 | $75.8K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 11, 2024 | OPTION EX. | 93,333 | $1.40 | $130.7K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 11, 2024 | OPTION EX. | 40,000 | — | — | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 11, 2024 | OPTION EX. | 75,000 | $1.01 | $75.8K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 11, 2024 | OPTION EX. | 40,000 | — | — | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Sep 11, 2024 | OPTION EX. | 93,333 | $1.40 | $130.7K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 2,071 | $3.87 | $8.0K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 43,485 | $0.94 | $40.9K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 38,953 | $1.31 | $51.0K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 15,000 | $3.87 | $58.0K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 12,418 | $2.72 | $33.8K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 6,492 | $1.84 | $11.9K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 1,825 | $3.00 | $5.5K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 11,000 | $1.84 | $20.2K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 55,000 | $1.31 | $72.0K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 31,500 | $2.72 | $85.7K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 55,000 | $0.94 | $51.7K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | OPTION EX. | 5,500 | $3.00 | $16.5K | Form 4 |
| PAKIANATHAN DEEPIKA | director | Aug 22, 2024 | SELL | 105,244 | $4.43 | $466.2K | Form 4 |
| Sermon Charles | General Counsel | Jun 25, 2024 | SELL | 14,202 | $3.69 | $52.5K | Form 4 |
| Sermon Charles | General Counsel | Jun 26, 2024 | SELL | 32,187 | $3.39 | $109.2K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Jun 25, 2024 | SELL | 7,416 | $3.69 | $27.4K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Jun 26, 2024 | SELL | 16,808 | $3.39 | $57.0K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Jun 25, 2024 | SELL | 12,990 | $3.69 | $48.0K | Form 4 |
| Fox Christine Ann | Chief Financial Officer | Jun 26, 2024 | SELL | 29,439 | $3.39 | $99.9K | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Jun 25, 2024 | SELL | 40,712 | $3.69 | $150.4K | Form 4 |
| Scots-Knight Denise | director, officer: Chief Executive Officer | Jun 26, 2024 | SELL | 92,273 | $3.39 | $313.1K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Jun 25, 2024 | SELL | 10,134 | $3.69 | $37.4K | Form 4 |
| Hughes-Wilson Alexandra | See Remarks | Jun 26, 2024 | SELL | 22,968 | $3.39 | $77.9K | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Jun 21, 2024 | OPTION EX. | 69,000 | — | — | Form 4 |
| Lewicki John A. | Chief Scientific Officer | Jun 21, 2024 | OPTION EX. | 69,000 | — | — | Form 4 |